More

Run HTS directly at Enamine or have your copy from
EDF在线老虎机 Ever-expanding collection of 3 million compounds

EDF在线老虎机Screening Libraries & HTS

NEWS

Dec 12, 2019

Dec 12, 2019

New RNA targeted library has been created!

“The number of targets, the number of diseases that one could go after by targeting RNA, is almost unimaginable,” says Matt Disney, a chemist at the Scripps Research Institute.

In response to growing interest and recent advancements in targeting RNA our experts designed dedicated library of small molecules predicted to bind to RNA targets. In contrast to the classical protein targets and disease treatment, drugging RNA reveals absolutely new way to treat and prevent different disorders.

Our freshly-made library is ready for fast shipment within a week in various custom formats.

RNA Library contains 8 960 compounds.EDF在线老虎机 Read more>>

120 000 Fragment compounds
including 10 000 covalent binders

Fragments

NEWS

EDF在线老虎机June 25, 2019

June 25, 2019

Enamine’s covalent fragments
produce potent and unique hits

In a recent JACS paper several academic groups collaborated on discovery of novel covalent inhibitors using a library of 993 acrylamides and chloroacetamides sourced from Enamine’s covalent fragment collection. The design was focusing on mild electrophiles that were supposed to overcome the selectivity challenge. The library was characterized by a new high-throughput thiol-reactivity assay and screened against 10 cysteine-containing proteins. Potent and unique primary hits have been found in the majority (7 out of 10) of cases.

A refined library used in the research with a few frequent hitters and excessively reactive fragments removed is available from Enamine on request >

Ref.: J. Am. Chem. Soc. 2019, 141, 8951−8968

Reach out to new chemical space breaking the availability bias:
11 000 000 000 molecules and beyond

REAL compounds

NEWS

June 24, 2019

June 24, 2019

Atomwise and Enamine to Advance Pediatric Oncology With the World’s First and Largest Ten Billion Compound Virtual Screen

10 Billion REAL compounds will be searched using AI powered drug screening platform to find novel small molecules for the treatment of pediatric cancers. In collaboration with academic researchers, Atomwise and Enamine said the “10-to-the-10 program” will seek to maximize the opportunity to develop drugs for new target proteins to inhibit cancer growth and metastasis. Read PRESS RELEASE >

The world’s largest collection of building blocks in stock:
184 345 and counting

New Building Blocks

A broad test panel to support lead discovery
Integrated projects or a-la-carte service

ADME/T & in-vivo PK

Scientific research and development of techniques for the synthesis of organic compounds

High Fidelity Fragments

High Fidelity Library

Fragments of high MedChem tractability  

REAL Database

The largest enumerated database of synthetically feasible molecules

Functional Compounds

Impurity Reference Standards
 

EDF在线老虎机Covalent Fragments

Covalent Fragments

Diverse covalent warheads with balanced reactivity

2 000 new building blocks are synthesized monthly. Here is an important update to our MedChem Highlights from January 2020

Recent News

  • 19 November 2019   Press Releases

    Optibrium collaborates with Enamine and BioSolveIT to add REAL ...

    Optibrium™, BioSolveIT™ and Enamine™ today announce a three-way collaboration enabling efficient search of Enamine’s REAL Space directly from within Optibrium’s StarDrop™ software。 This extension to StarDrop is powered by BioSolveIT’s proprietary Feature Trees (FTrees) technology, to search a gigantic chemical space of over 11 billion readily accessible compounds and identify novel compounds that are similar to a query structure of interest。 The resulting chemical structures and data are pre-formatted and ready to evaluate using StarDrop’s comprehensive suite of integrated software for small molecule design, optimisation and data analysis。

    Read press release

  • 05 November 2019   Press Releases

    EDF在线老虎机Cyclica Collaborates With Enamine to Use REAL Technology in ...

    Cyclica, Inc. announced a collaboration with Enamine Ltd. to explore its huge readily accessible chemical space using Cyclica’s state-of-the-art AI-driven Ligand Design™ platform. The companies aim to empower Cyclica’s patented, evolutionary algorithm with new design options based on the 73,000 Enamine’s in-stock building blocks and 171 thoroughly validated synthesis procedures. The joint effort is expected to enable Cyclica’s Ligand Design™ to identify novel molecules with desired polypharmacological properties out of over 11 billion REAL™ (readily accessible) compounds. At least 80% of these compounds will be synthesized by Enamine within only 3-4 weeks.

    Read press release

  • 05 September 2019   News

    Enamine to boost synthesis of DNA-Encoded Libraries

    Meet our delegates at International Symposium on DEL in Zurich to learn on our approaches in selecting DEL-compatible building blocks and on our advances in intriguing designs of novel chemotypes >>>

Upcoming events

  • Mar 22 - 25

    Exhibitor, Sponsoring

    Frelburg, Germany

  • Apr 23 - 24

    Exhibitor, Sponsoring

    Braunschweig, Germany

  • Feb 24 - 25

    Delegates, Sponsoring

    Cambridge, UK

Scientia pharmaceutica , 2013, 81 (2), 359-391

DOI: 10.3797/scipharm.1211-08

Kovalenko S. I.; Antypenko L. M.; Bilyi A. K.; Kholodnyak S. V.; Karpenko O. V.; Antypenko O. M.; Mykhaylova N. S.; Los T. I.; Kolomoets O. S.

The combinatorial library of novel potential anticancer agents, namely, 2-(alkyl-, alkaryl-, aryl-, hetaryl-)[1,2,4]triazolo[1,5-c]quinazolines, was synthesized by the heterocyclization of the alkyl-, alkaryl-, aryl-, hetarylcarboxylic acid (3H-quinazoline-4-ylidene)hydrazides by oxidative heterocyclization of the 4-(arylidenehydrazino)quinazolines using bromine, and by the heterocyclization of N-(2-cyanophenyl)formimidic acid ethyl ester. The optimal method for synthesis of the s-triazolo[1,5-c]quinazolines appeared to be cyclocondensation of the corresponding carboxylic acid (3H-quinazoline-4-ylidene)hydrazides. The compounds' structures were established by 1H, 13C NMR, LC- and EI-MS analysis. The in vitro screening of anticancer activity determined the most active compound to be 3,4,5-trimethoxy-N'-[quinazolin-4(3H)-ylidene]benzohydrazide (3.20) in micromolar concentrations with the GI50 level (MG_MID, GI50 is 2.29). Thus, the cancer cell lines whose growth is greatly inhibited by compound 3.20 are: non-small cell lung cancer (NCI-H522, GI50=0.34), CNS (SF-295, GI50=0.95), ovarian (OVCAR-3, GI50=0.33), prostate (PC-3, GI50=0.56), and breast cancer (MCF7, GI50=0.52), leukemia (K-562, GI50=0.41; SR, GI50=0.29), and melanoma (MDA-MB-435, GI50=0.31; SK-MEL-5, GI50=0.74; UACC-62, GI50=0.32). SAR-analysis is also discussed.

Synthesis and Anticancer Activity of 2-(Alkyl-, Alkaryl-, Aryl-, Hetaryl-)-[1,2,4]triazolo[1,5-c]quinazolines.

Kovalenko S. I.; Antypenko L. M.; Bilyi A. K.; Kholodnyak S. V.; Karpenko O. V.; Antypenko O. M.; Mykhaylova N. S.; Los T. I.; Kolomoets O. S.
Scientia pharmaceutica 2013, 81 (2), 359-391
DOI: 10.3797/scipharm.1211-08

FOLLOW US

公益福彩app AG体育 皇冠体育网 山东群英会技巧 天天斗牛